<?xml version="1.0" encoding="UTF-8"?>
<modsCollection xmlns="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd">
  <mods>
    <titleInfo>
      <title>Discovery of antileishmanial hits in the 3-nitroimidazo[1,2-a]pyridine series via newly optimized tetrakis(dimethylamino)ethylene (TDAE) methodology at position 2</title>
    </titleInfo>
    <name type="personnal">
      <namePart type="family">Jacquet</namePart>
      <namePart type="given">I.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Paoli-Lombardo</namePart>
      <namePart type="given">R.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Castera-Ducros</namePart>
      <namePart type="given">C.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Pomares</namePart>
      <namePart type="given">H.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Bourgeade-Delmas</namePart>
      <namePart type="given">Sandra</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Vanelle</namePart>
      <namePart type="given">P.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Primas</namePart>
      <namePart type="given">N.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <typeOfResource>text</typeOfResource>
    <genre authority="local">journalArticle</genre>
    <language>
      <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
    </language>
    <physicalDescription>
      <internetMediaType>text/pdf</internetMediaType>
      <digitalOrigin>reformatted digital</digitalOrigin>
      <reformattingQuality>access</reformattingQuality>
    </physicalDescription>
    <abstract>To explore the antileishmanial structure-activity relationships at position 2 of the 3-nitroimida-zo[1,2-a]pyridine scaffold, we developed a new synthetic method using Tetrakis(dimethylamino)ethylene (TDAE) and N-tosylbenzylimines. This original synthetic route was optimized to provide simple and reproducible access to diverse analogues functionalized at position 2. A library of 25 new derivatives was generated via efficient diversification at position 8 using nucleophilic aromatic substitution (SNAr) and Suzuki-Miyaura cross-coupling reactions. The 8-brominated analogues emerged as the most promising series, with six compounds exhibiting submicromolar activity against Leishmania infantum axenic amastigotes. Further substitution at position 8 with 4-pyridinyl or para-chlorothiophenol groups significantly decreased potency. The most active compound was also active on intramacrophagic amastigotes (half maximal inhibitory concentration (IC50) = 0.35 mu M) without displaying any cytotoxicity on THP1 cell line (50 % cytotoxic concentration (CC50) &gt; 100 mu M). The reduction of its nitro group afforded an amino analogue, which retained antileishmanial activity (IC50 = 2.77 mu M), indicating potential alternative mechanisms of action beyond nitro bioactivation. Despite its low solubility (&lt;1 mu M), this scaffold represents a novel and versatile entry point for antileishmanial drug discovery.</abstract>
    <targetAudience authority="marctarget">specialized</targetAudience>
    <subject>
      <topic>TDAE</topic>
      <topic>N-Tosylbenzylimine</topic>
      <topic>Leishmania</topic>
      <topic>Nitroaromatic compounds</topic>
      <topic>Nucleophilic aromatic substitution</topic>
      <topic>Palladium-catalyzed cross-coupling</topic>
      <topic>3-Nitroimidazo[1,2-a]pyridine</topic>
    </subject>
    <classification authority="local">020</classification>
    <classification authority="local">050</classification>
    <classification authority="local">052</classification>
    <relatedItem type="host">
      <titleInfo>
        <title>European Journal of Medicinal Chemistry</title>
      </titleInfo>
      <part>
        <detail type="volume">
          <number>304</number>
        </detail>
        <extent unit="pages">
          <list>118506 [14 ]</list>
        </extent>
      </part>
      <originInfo>
        <dateIssued>2026</dateIssued>
      </originInfo>
      <identifier type="issn">0223-5234</identifier>
    </relatedItem>
    <identifier type="uri">https://www.documentation.ird.fr/hor/fdi:010096002</identifier>
    <identifier type="doi">10.1016/j.ejmech.2025.118506</identifier>
    <identifier type="issn">0223-5234</identifier>
    <location>
      <shelfLocator>[F B010096002]</shelfLocator>
      <url usage="primary display" access="object in context">https://www.documentation.ird.fr/hor/fdi:010096002</url>
      <url access="row object">https://horizon.documentation.ird.fr/exl-doc/pleins_textes/2026-02/010096002.pdf</url>
    </location>
    <recordInfo>
      <recordContentSource>IRD - Base Horizon / Pleins textes</recordContentSource>
      <recordCreationDate encoding="w3cdtf">2026-02-04</recordCreationDate>
      <recordChangeDate encoding="w3cdtf">2026-02-05</recordChangeDate>
      <recordIdentifier>fdi:010096002</recordIdentifier>
      <languageOfCataloging>
        <languageTerm authority="iso639-2b">fre</languageTerm>
      </languageOfCataloging>
    </recordInfo>
  </mods>
</modsCollection>
